Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: "Mark A Rubin" Clear advanced filters
  • To get targeted treatments to more cancer patients pair genomic data with clinical data, and make the information widely accessible, urges Mark A. Rubin.

    • Mark A. Rubin
    Comments & Opinion
    Nature
    Volume: 520, P: 290-291
  • Fraser and colleagues describe the whole-genome sequencing (WGS) profiles of over 200 localized intermediate-risk prostate cancers. WGS has been widely used in research but not, thus far, in clinical settings. Herein, we consider the possible use of WGS in the field of precision oncology.

    • Marcin Imielinski
    • Mark A. Rubin
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 14, P: 265-266
  • Whole-genome sequencing reveals the duplication of a regulatory region, called an enhancer, of the AR gene in treatment-resistant human prostate cancers. The finding shows the importance of analysing non-protein-coding regions of DNA.

    • Kellie A. Cotter
    • Mark A. Rubin
    News & Views
    Nature
    Volume: 560, P: 557-559
  • Genomic analyses of cancer genomes have largely focused on mutations in protein-coding regions, but the functional importance of alterations to non-coding regions is becoming increasingly appreciated through whole-genome sequencing. This Review discusses our current understanding of non-coding sequence variants in cancer — both somatic mutations and germline variants, and their interplay — including their identification, computational and experimental evidence for functional impact, and their diverse mechanisms of action for dysregulating coding genes and non-coding RNAs.

    • Ekta Khurana
    • Yao Fu
    • Mark Gerstein
    Reviews
    Nature Reviews Genetics
    Volume: 17, P: 93-108
  • The use of CRISPR–Cas technology for gene editing has rapidly become widespread. Here, Corn and colleagues discuss the applications of this revolutionary tool in drug discovery and development, describing how it could make substantial contributions to target identification and validation, animal models and cell-based therapies.

    • Christof Fellmann
    • Benjamin G. Gowen
    • Jacob E. Corn
    Reviews
    Nature Reviews Drug Discovery
    Volume: 16, P: 89-100